

Non-alcoholic Fatty Liver Disease Therapeutics Market Size, Trends, Analysis, and Outlook By Type (Antioxidants, Thiazolidinedione), By Application (Hospital Pharmacy, Retail Pharmacy, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/N0AAC0C9D8D8EN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: N0AAC0C9D8D8EN

Abstracts

The global Non-alcoholic Fatty Liver Disease Therapeutics market size is poised to register 13.37% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Non-alcoholic Fatty Liver Disease Therapeutics market By Type (Antioxidants, Thiazolidinedione), By Application (Hospital Pharmacy, Retail Pharmacy, Others).

The future of non-alcoholic fatty liver disease (NAFLD) therapeutics is driven by advancements in hepatology, metabolic medicine, and drug development aimed at addressing the underlying mechanisms of hepatic steatosis, inflammation, and fibrosis in patients with this increasingly prevalent liver condition. Key trends include the development of targeted pharmacotherapies, such as peroxisome proliferator-activated receptor (PPAR) agonists, farnesoid X receptor (FXR) agonists, and anti-inflammatory agents, that modulate lipid metabolism, insulin sensitivity, and hepatic inflammation to prevent disease progression and improve liver function. Additionally, there is a growing emphasis on the integration of lifestyle interventions, such as dietary modifications, exercise programs, and weight management strategies, into NAFLD treatment protocols to address metabolic risk factors, promote weight loss, and reduce hepatic fat accumulation. Moreover, advancements in non-invasive diagnostic techniques, imaging biomarkers, and patient stratification strategies enable early detection, risk assessment, and personalized treatment approaches for NAFLD patients, driving continuous innovation and adoption of NAFLD therapeutics in hepatology practice, clinical trials, and public health initiatives..

Non-alcoholic Fatty Liver Disease Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Non-alcoholic Fatty Liver Disease Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Non-alcoholic Fatty Liver Disease Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Non-alcoholic Fatty Liver Disease Therapeutics industry.

Key market trends defining the global Non-alcoholic Fatty Liver Disease Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Non-alcoholic Fatty Liver Disease Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Non-alcoholic Fatty Liver Disease Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Non-alcoholic Fatty Liver Disease Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Non-alcoholic Fatty Liver Disease Therapeutics industry

Leading Non-alcoholic Fatty Liver Disease Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies

are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Non-alcoholic Fatty Liver Disease Therapeutics companies.

Non-alcoholic Fatty Liver Disease Therapeutics Market Study- Strategic Analysis Review

The Non-alcoholic Fatty Liver Disease Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Non-alcoholic Fatty Liver Disease Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Non-alcoholic Fatty Liver Disease Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Non-alcoholic Fatty Liver Disease Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe,

the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Non-alcoholic Fatty Liver Disease Therapeutics Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Non-alcoholic Fatty Liver Disease Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Non-alcoholic Fatty Liver Disease Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Non-alcoholic Fatty Liver Disease Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Non-alcoholic Fatty Liver Disease Therapeutics Market Size Outlook- Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Non-alcoholic Fatty Liver Disease Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Non-alcoholic Fatty Liver Disease Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Non-alcoholic Fatty Liver Disease Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Non-alcoholic Fatty Liver Disease Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Non-alcoholic Fatty Liver Disease Therapeutics markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking

growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Non-alcoholic Fatty Liver Disease Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Non-alcoholic Fatty Liver Disease Therapeutics Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Non-alcoholic Fatty Liver Disease Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Non-alcoholic Fatty Liver Disease Therapeutics.

Non-alcoholic Fatty Liver Disease Therapeutics Market Company Profiles

The global Non-alcoholic Fatty Liver Disease Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Allergan, AstraZeneca Plc, Cardax, Daewoong, Gilead Sciences, GW Pharmaceuticals, Limerick BioPharma, Merck, Novartis AG, Pfizer Inc, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Co. Ltd.

Recent Non-alcoholic Fatty Liver Disease Therapeutics Market Developments

The global Non-alcoholic Fatty Liver Disease Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Non-alcoholic Fatty Liver Disease Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Allergan

AstraZeneca Plc

Cardax

Daewoong

Gilead Sciences

GW Pharmaceuticals

Limerick BioPharma

Merck

Novartis AG

Pfizer Inc

F. Hoffmann-La Roche Ltd

Takeda Pharmaceutical Co. Ltd

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Non alcoholic Fatty Liver Disease Therapeutics Market Overview and Key Findings, 2024
- 1.2 Non alcoholic Fatty Liver Disease Therapeutics Market Size and Growth Outlook, 2021- 2030
- 1.3 Non alcoholic Fatty Liver Disease Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Non alcoholic Fatty Liver Disease Therapeutics Market Trends and Challenges
 - 1.4.1 Non alcoholic Fatty Liver Disease Therapeutics Market Drivers and Trends
 - 1.4.2 Non alcoholic Fatty Liver Disease Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Non alcoholic Fatty Liver Disease Therapeutics Companies

2. NON ALCOHOLIC FATTY LIVER DISEASE THERAPEUTICS MARKET SIZE OUTLOOK TO 2030

- 2.1 Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook, USD Million, 2021- 2030
- 2.2 Non alcoholic Fatty Liver Disease Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. NON ALCOHOLIC FATTY LIVER DISEASE THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. NON ALCOHOLIC FATTY LIVER DISEASE THERAPEUTICS MARKET

SEGMENTATION ANALYSIS AND OUTLOOK

4.1 Market Segmentation and Scope

4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Non alcoholic Fatty Liver Disease Therapeutics Market, 2025

5.2 Asia Pacific Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Non alcoholic Fatty Liver Disease Therapeutics Market, 2025

5.5 Europe Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Type, 2021- 2030

5.6 Europe Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Non alcoholic Fatty Liver Disease Therapeutics Market, 2025

5.8 North America Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Type, 2021- 2030

5.9 North America Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Non alcoholic Fatty Liver Disease Therapeutics Market, 2025

5.11 South America Pacific Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Type, 2021- 2030

5.12 South America Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Non alcoholic Fatty Liver Disease Therapeutics Market, 2025

5.14 Middle East Africa Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

6.1 US Non alcoholic Fatty Liver Disease Therapeutics Market Size Outlook and Revenue Growth Forecasts

6.2 US Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities

- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities

- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Non alcoholic Fatty Liver Disease Therapeutics Industry Drivers and Opportunities

7. NON ALCOHOLIC FATTY LIVER DISEASE THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. NON ALCOHOLIC FATTY LIVER DISEASE THERAPEUTICS COMPANY PROFILES

- 8.1 Profiles of Leading Non alcoholic Fatty Liver Disease Therapeutics Companies in the Market
 - 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
 - 8.3 Financial Performance and Key Metrics
- Allergan
 - AstraZeneca Plc
 - Cardax
 - Daewoong
 - Gilead Sciences
 - GW Pharmaceuticals
 - Limerick BioPharma
 - Merck
 - Novartis AG

Pfizer Inc
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Co. Ltd

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

I would like to order

Product name: Non-alcoholic Fatty Liver Disease Therapeutics Market Size, Trends, Analysis, and Outlook By Type (Antioxidants, Thiazolidinedione), By Application (Hospital Pharmacy, Retail Pharmacy, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/N0AAC0C9D8D8EN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N0AAC0C9D8D8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970